Mycobacterium Avium Complex clinical trials at UCSF

1 research study open to eligible people

Mycobacterium avium complex is an infection caused by bacteria that can affect the lungs. UCSF is conducting trials to see if two antibiotics are as effective as three in treating this infection. The studies will help improve treatment methods.

Showing trials for

  • Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

    open to eligible people ages 18 years and up

    NTM therapy consists of a multi-drug macrolide based regimen for 18-24 months. Treated patients frequently experience debilitating side effects, and many patients delay the start of antibiotic treatment due to these risks. Common side effects include nausea, diarrhea, and fatigue, and rare but serious toxicities include ocular toxicity, hearing loss, and hematologic toxicity. To date, most of the evidence underlying the current treatment recommendations has come from observational studies in which either a macrolide has been combined with rifampin and ethambutol, or in some cases combined with ethambutol alone. The proposed study will answer whether a third drug is necessary or whether taking two drugs can increase tolerability without a substantial loss of efficacy.

    San Francisco, California and other locations

Our lead scientists for Mycobacterium Avium Complex research studies include .

Last updated: